Articles - Heart Health

To provide a national assessment of cardiovascular risk factors and disease mortality among Asian Indian, Chinese, and Filipino American subgroups in the United States.

In this study, we analyzed data from 45,250 participants from the National Health and Nutrition Examination Survey spanning 1999 to 2020. Using multivariable logistic regression, we explored the association between CMI and hypertension, employing Restricted Cubic Spline analysis to assess non-linear relationships and two-piecewise linear regression to identify threshold effects.

The purpose of this study was to examine the cardiovascular benefits of tirzepatide vs GLP-1RA in people living with overweight or obesity, with T2DM, age ≥40 years, and pre-existing ischemic heart disease (IHD).

In this clinical practice statement, we aim to provide a roadmap of the path forward in each of these domains for health care providers and health systems, community outreach groups, and stakeholders invested in investigation and policy to mitigate risk and empower SAs to lead healthy lives.

Asia is a large continent that comprises diverse populations with varying cultures, socioeconomic status, and health literacy levels. Effective preventive cardiology may require differential health care resource allocation and financing models.

The pivotal role of nutrition interventions in the context of dyslipidemia and its cardiometabolic implications is discussed in this review, emphasizing evidence-based and personalized approaches.

This article highlights these and other potential solutions for therapeutic non-adherence and inertia, as discussed at the 2024 Evidence in the Cardiometabolic Environment (EVIDENT) Summit.

The importance of this has been emphasised once again by the Investigators of the Global Burden of Diseases (GBD), in the article published in this issue of Metabolism, showing that metabolic diseases continue to pose significant health challenges, although there are important differences in health burdens that have occurred over the last 30 years.

This review explores recent advancements in our understanding of CVD in women. We summarise the underlying factors unique to women that can promote CVD risk factors, ultimately contributing to CVD burden and the emerging therapies aimed to combat this.

With such a high burden of mortality, it is imperative that countries embrace innovative approaches to control the rising burden and strengthen health systems, in order to reduce the preventable mortality from these diseases.

To improve upon the estimation of 10-year cardiovascular disease (CVD) event risk for individuals without prior CVD or diabetes mellitus in the Asia-Pacific region by systematic recalibration of the SCORE2 risk algorithm.

We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure.

Given the rapidly growing burden of cardiovascular disease (CVD) in Asia, this study forecasts the CVD burden and associated risk factors in Asia from 2025 to 2050.

The aim of this study was to investigate the synergistic effect of general and central obesity with dyslipidemia on the risk of HTN.

This joint expert review by the Obesity Medicine Association (OMA) and National Lipid Association (NLA) provides clinicians an overview of the pathophysiologic and clinical considerations regarding obesity, dyslipidemia, and cardiovascular disease (CVD) risk.

This article reviews available evidence regarding hypertension management in the Asia-Pacific region, focussing on five research questions that deal with specific aspects: blood pressure (BP) control, guideline recommendations, role of renin–angiotensin–aldosterone system (RAAS) inhibitors in clinical practice, pharmacological management and real-world adherence to guideline recommendations.

The goal of this article is to characterize the endothelium’s role in the development of hypertension and dyslipidemia and to point out promising therapeutic directions.

This study aimed to assess the proportion and trends of Asian race participants and APAC authorship in cardiometabolic trials.

The Asian Pacific Society of Cardiology (APSC) developed these consensus recommendations to address the need for a unified approach to managing dyslipidaemia. These recommendations are intended to guide general cardiologists and internists in the assessment and treatment of dyslipidaemia and are hoped to pave the way for improving screening, early diagnosis and treatment.

A systematic review aiming to assess the prevalence of hypertension and its risk factors among the urban population in Southeast Asian countries was conducted. We performed database searches of PubMed and Web of Science and performed meta-analysis to determine the pooled prevalence estimate.

The aim of this review is to highlight the fundamental aspects of the diagnostic criteria, pathophysiology, and the treatment of the dyslipidemia in cardiometabolic syndrome.

Based on the main findings from the Systolic Blood Pressure Intervention Trial (SPRINT) and several recent meta-analyses, the HT committee members of the Taiwan Society of Cardiology and the Taiwan Hypertension Society convened and finalized the revised BP targets for management of HT. We suggested a new systolic BP target to < 120mmHg for patients with coronary heart disease, chronic kidney disease with an eGFR of 20-60 ml/min/1.73 m2, and elderly patients aged 75 years, using unattended automated office BP measurement.